Cargando…
Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377608/ https://www.ncbi.nlm.nih.gov/pubmed/34410325 http://dx.doi.org/10.1001/jamaophthalmol.2021.3096 |
_version_ | 1783740690716426240 |
---|---|
author | Li, Tong Sun, Junran Min, Jingyu Zhou, Shuangwen Zhu, Xiaolin Jia, Huixun Sun, Xiaodong |
author_facet | Li, Tong Sun, Junran Min, Jingyu Zhou, Shuangwen Zhu, Xiaolin Jia, Huixun Sun, Xiaodong |
author_sort | Li, Tong |
collection | PubMed |
description | IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated. OBJECTIVE: To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched from inception to July 2020. STUDY SELECTION: Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies, extracted data, and assessed risk of bias. A meta-analysis was conducted to determine the rates of endophthalmitis (EO) and culture-positive EO. MAIN OUTCOMES AND MEASURES: Rates of EO and culture-positive EO following anti-VEGF IVIs in the OR and office-based setting. RESULTS: Thirty-one studies with a total of 1 275 815 injections were included. Comparative analysis suggested no difference between rates of EO after IVIs performed in the office and OR settings (odds ratio, 3.06; 95% CI, 0.07-139.75; P = .57; I(2) = 80%) were identified, yet a higher rate of culture-positive EO was found in the office setting (odds ratio, 21.52; 95% CI, 2.39-193.55; P = .006; I(2) = 0%). The pooled rates of EO following anti-VEGF IVIs were 0.03% (95% CI, 0.03-0.04) and 0.02% (95% CI, 0.01-0.04) in office and OR settings, respectively, and the pooled rates of culture-positive EO were 0.01% (95% CI, 0.01-0.02) and 0.01% (95% CI, 0-0.02). The pooled rates of other ocular and systemic adverse events were low. CONCLUSIONS AND RELEVANCE: The rate of clinically suspected or culture-positive EO following anti-VEGF IVIs was low whether the procedure was performed in the office or OR setting. Bacterial spectrum could differ between the 2 settings. This meta-analysis could not determine if it is more appropriate to give treatment in the OR for safety reasons in low-income compared with higher-income regions in the world. |
format | Online Article Text |
id | pubmed-8377608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-83776082021-09-02 Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis Li, Tong Sun, Junran Min, Jingyu Zhou, Shuangwen Zhu, Xiaolin Jia, Huixun Sun, Xiaodong JAMA Ophthalmol Original Investigation IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated. OBJECTIVE: To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched from inception to July 2020. STUDY SELECTION: Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies, extracted data, and assessed risk of bias. A meta-analysis was conducted to determine the rates of endophthalmitis (EO) and culture-positive EO. MAIN OUTCOMES AND MEASURES: Rates of EO and culture-positive EO following anti-VEGF IVIs in the OR and office-based setting. RESULTS: Thirty-one studies with a total of 1 275 815 injections were included. Comparative analysis suggested no difference between rates of EO after IVIs performed in the office and OR settings (odds ratio, 3.06; 95% CI, 0.07-139.75; P = .57; I(2) = 80%) were identified, yet a higher rate of culture-positive EO was found in the office setting (odds ratio, 21.52; 95% CI, 2.39-193.55; P = .006; I(2) = 0%). The pooled rates of EO following anti-VEGF IVIs were 0.03% (95% CI, 0.03-0.04) and 0.02% (95% CI, 0.01-0.04) in office and OR settings, respectively, and the pooled rates of culture-positive EO were 0.01% (95% CI, 0.01-0.02) and 0.01% (95% CI, 0-0.02). The pooled rates of other ocular and systemic adverse events were low. CONCLUSIONS AND RELEVANCE: The rate of clinically suspected or culture-positive EO following anti-VEGF IVIs was low whether the procedure was performed in the office or OR setting. Bacterial spectrum could differ between the 2 settings. This meta-analysis could not determine if it is more appropriate to give treatment in the OR for safety reasons in low-income compared with higher-income regions in the world. American Medical Association 2021-08-19 2021-10 /pmc/articles/PMC8377608/ /pubmed/34410325 http://dx.doi.org/10.1001/jamaophthalmol.2021.3096 Text en Copyright 2021 Li T et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Li, Tong Sun, Junran Min, Jingyu Zhou, Shuangwen Zhu, Xiaolin Jia, Huixun Sun, Xiaodong Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title | Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title_full | Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title_fullStr | Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title_full_unstemmed | Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title_short | Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis |
title_sort | safety of receiving anti–vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377608/ https://www.ncbi.nlm.nih.gov/pubmed/34410325 http://dx.doi.org/10.1001/jamaophthalmol.2021.3096 |
work_keys_str_mv | AT litong safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT sunjunran safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT minjingyu safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT zhoushuangwen safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT zhuxiaolin safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT jiahuixun safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis AT sunxiaodong safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis |